LMGAM
ALXN

Liberty Mutual Group Asset Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Liberty Mutual Group Asset Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-8,894
Closed -$1.24M – 870
2018
Q3 		$1.24M Hold
8,894
– – 0.03% 288
2018
Q2 		$1.1M Sell
8,894
-1
-0% -$117 0.03% 333
2018
Q1 		$991K Hold
8,895
– – 0.03% 385
2017
Q4 		$1.06M Sell
8,895
-198
-2% -$24.1K 0.03% 421
2017
Q3 		$1.28M Sell
9,093
-5,034
-36% -$684K 0.07% 333
2017
Q2 		$1.72M Buy
14,127
+1,762
+14% +$205K 0.07% 372
2017
Q1 		$1.5M Sell
12,365
-3,967
-24% -$511K 0.06% 475
2016
Q4 		$2M Buy
16,332
+839
+5% +$103K 0.07% 354
2016
Q3 		$1.9M Sell
15,493
-529
-3% -$68.1K 0.07% 355
2016
Q2 		$1.87M Buy
16,022
+1,156
+8% +$164K 0.07% 335
2016
Q1 		$2.07M Buy
14,866
+1,344
+10% +$197K 0.09% 258
2015
Q4 		$2.58M Buy
13,522
+409
+3% +$71.4K 0.1% 262
2015
Q3 		$2.05M Sell
13,113
-46
-0.3% -$8.39K 0.08% 313
2015
Q2 		$2.38M Sell
13,159
-3,933
-23% -$679K 0.08% 293
2015
Q1 		$2.96M Buy
17,092
+835
+5% +$151K 0.09% 244
2014
Q4 		$3.01M Buy
16,257
+178
+1% +$33K 0.09% 237
2014
Q3 		$2.67M Sell
16,079
-387
-2% -$63.6K 0.09% 272
2014
Q2 		$2.57M Sell
16,466
-1,661
-9% -$262K 0.08% 294
2014
Q1 		$2.76M Buy
18,127
+2,248
+14% +$357K 0.09% 230
2013
Q4 		$2.11M Buy
15,879
+4,071
+34% +$489K 0.07% 301
2013
Q3 		$1.37M Buy
11,808
+2,511
+27% +$275K 0.05% 449
2013
Q2 		$857K Buy
+9,297
New +$896K 0.03% 632

Other funds holding ALXN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Liberty Mutual Group Asset Management's ALXN Position: Q4 2018 in Review

Liberty Mutual Group Asset Management sold out of Alexion Pharmaceuticals (ALXN) in Q4 2018, closing a stake of 8,894 shares — an estimated $1.24M sold.

Liberty Mutual Group Asset Management first reported a position in ALXN in Q2 2013 and held it in 22 quarters. The position peaked at $3.01M in Q4 2014. 608 funds tracked by Wall St. Rank hold ALXN as of Q4 2018.

  • Liberty Mutual Group Asset Management reported no remaining Alexion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Liberty Mutual Group Asset Management sold 8,894 Alexion Pharmaceuticals shares in Q4 2018, an estimated $1.24M.
  • Liberty Mutual Group Asset Management first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 22 quarters.
  • Liberty Mutual Group Asset Management's Alexion Pharmaceuticals position peaked at $3.01M in Q4 2014.
  • 608 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2018.

Based on Liberty Mutual Group Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.